You are here: Industry Insights > Multiple

News List

Multiple myeloma treatment granted Orphan Drug Designation europeanpharmaceuticalreview
September 19, 2019
Orphan Drug Designation has been given to bispecific antibody candidate, GBR 1342, for the treatment of multiple myeloma.
Glenmark Receives Orphan Drug Designation for Multiple Myeloma Candidate americanpharmaceuticalreview
September 18, 2019
Glenmark announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its bispecific antibody candidate GBR 1342 for the treatment of patients with multiple myeloma ...
DARZALEX® Study Data Show High Response Rate americanpharmaceuticalreview
September 17, 2019
The Janssen Pharmaceutical Companies of Johnson & Johnson announced results from the randomized Phase 2 GRIFFIN (MMY2004) study showing that the addition of DARZALEX® (daratumumab) to bortezomib ...
Roche presents new 6-year OCREVUS (ocrelizumab) data which showed that earlier initiation and continuation of treatment reduced disability progression in multiple sclerosis worldpharmanews
September 17, 2019
Roche announced longer-term data from the Phase III open-label extension studies of OPERA I, OPERA II and ORATORIO showed that patients who were treated with OCREVUS® (ocrelizumab) continuously for ...
Serum Biomarker Linked to Brain Atrophy in Multiple Sclerosis drugs
September 12, 2019
Serum neurofilament light chain (sNFL) levels are significantly associated with clinical and neuroimaging outcomes in multiple sclerosis (MS), according to a study published online in JAMA Neurology.
Sandoz announces global deal to commercialize proposed biosimilar natalizumab, a key multiple sclerosis medicine worldpharmanews
September 06, 2019
Sandoz, a Novartis division and a global leader in biosimilars, announced that it has entered into a global commercialization agreement for a proposed natalizumab biosimilar.
Sandoz licences proposed multiple sclerosis biosimilar from Polpharma pharmaceutical-technology
September 04, 2019
Novartis unit Sandoz has signed an agreement with biopharmaceutical firm Polpharma Biologics for exclusive rights to commercialise a proposed biosimilar of Biogen’s multiple sclerosis drug natalizumab.
Multiple myeloma treatment receives Orphan Drug Designation europeanpharmaceuticalreview
September 03, 2019
Orphan drug designation has been granted to the CT053 anti-BCMA CAR-T program for multiple myeloma treatment.
For Medicare Patients, Costs of MS Drugs Rise Sevenfold Over 10 Years drugs
August 30, 2019
Medicare patients with multiple sclerosis (MS) saw their medication costs soar by more than sevenfold over a decade, a new study finds.
Long-Term Night-Shift Work May Up Risk for Multiple Sclerosis drugs
August 29, 2019
A history of 20+ years of rotating night-shift work is associated with an increased risk for definite diagnosis of multiple sclerosis (MS)...

Previous page 1 2 3 Next page